JAN 24, 2017 2:06 PM PST

Errors During B Cell Metabolism Cause Lymphoma and Other Diseases

WRITTEN BY: Kara Marker

B cells are the multi-taskers of the immune system, and their different duties require different amounts of energy. A new study focused on the protein that acts as a B cell “handler,” and it could be a target for future treatments for different diseases, including lymphoma.

A germinal center (rectangle) in the spleen of an immunized mouse, showing inactivated GSK3 (magenta) in B cells (blue) near follicular dendritic cells (green). 

Depending on whether B cells are actively involved in an immune response, resting dormant or busy cultivating immune memory, they have different levels of metabolic needs to keep them functioning. A protein called GSK3 controls B cell metabolism to meet the needs of B cells, whether they are in a germinal center or in circulation.

"Our research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states," said Robert Rickert, Ph.D. "It acts as a metabolic sensor, or checkpoint, that promotes the survival of circulating B cells while limiting growth and proliferation of B cells in germinal centers.” 

For circulating cells, GSK3 prevents B cells from going overboard on metabolic activity. But for cells in a germinal center, where B cells proliferate and “hypermutate” their antibody genes to produce the most high-affinity antibodies, GSK3 limits glycolysis and mitochondrial production to ensure germinal B cell survival.

“The findings are particularly relevant for certain B cell pathologies, including lymphoma subtypes, where there is an increased demand for energy to support the hyperproliferation of cells in a microenvironment that may be limited in nutrients,” Rickert said.

Rickert’s study focused on why GSK3 is so vital to germinal B cells, which require large amounts of energy. To obtain the energy they need, they consume a lot of sugars, fatty acids, and amino acids to the point where they consume nearly all of the glucose that’s available to them. Then they result to obtaining energy from glycolysis, a secondary, less efficient, and non-oxygen-dependent energy production method.

Unfortunately, too much glycolytic activity leads to an overload of reactive oxygen species (ROS), which is toxic to the body’s cells. Therefore, GSK3 is saving germinal B cells from ROS-induced cell death because of its ability to limit glycolysis.

"Until now, we would have thought that slowing metabolism would only be important for preventing B cells from becoming cancerous, which it indeed may be,” Rickert said. “These studies provide insight into the dynamic nature of B cell metabolism that literally 'fuels' differentiation in the germinal center to produce an effective antibody response."

The recent study could support new studies for treating lymphoma, depending on how this particular type of cancer is related to B cell metabolism. "It's not yet clear whether or how GSK3 might be a target for future therapies for B cell-related diseases,” Rickert explained. “But this research opens a lot of doors for further studies.”

Rickert’s research was recently published in the journal Nature Immunology.

Source: Sanford-Burnham Prebys Medical Discovery Institute

Image credit: Laboratory of Robert Rickert, Ph.D., at Sanford Burnham Prebys Medical Discovery Institute

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean ...
FEB 21, 2020
Drug Discovery & Development
FEB 21, 2020
Why is it so Difficult to Develop a Vaccine for Coronavirus?
As of February 21st, 2,250 have died worldwide from Coronavirus, while 18,862 have recovered and 55,703 are currently in ...
APR 15, 2020
Immunology
APR 15, 2020
Does COVID-19 Attack the Immune System like HIV?
Researchers from the US and China have found that COVID-19 can destroy T cells, a type of lymphocyte that plays a key ro ...
APR 29, 2020
Immunology
APR 29, 2020
New Immune Cell Discovered in Mammary Ducts
Dubbed “ductal macrophages,” newly discovered immune cells found in breast tissue offer fresh promise for fu ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
Loading Comments...